[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354429-105":3,"doc-detail-354429-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-dual-channel-synergistic-ultrasensitive-biosensor-for-tumor-liquid-biopsy","A Dual-Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy","","Liquid biopsy technology detects circulating tumor DNA (ctDNA) in cerebrospinal fluid and supports early diagnosis and precision treatment of gliomas, but ctDNA’s low abundance and rapid clearance limit conventional methods such as droplet digital PCR and next-generation sequencing. A label-free dual-channel synergistic detection strategy quantifies ctDNA at the zeptomolar level by combining structural symmetry breaking and momentum regulation, plus DNA tetrahedron-hybridization chain reaction-gold nanoparticle cascade amplification.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-dual-channel-synergistic-ultrasensitive-biosensor-for-tumor-liquid-biopsy/354429/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-dual-channel-synergistic-ultrasensitive-biosensor-for-tumor-liquid-biopsy/354429.png","ImageObject",300,407,{"name":42,"@type":43},"Well Done","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical problem does the document address in glioma liquid biopsy?","Question",{"text":63,"@type":64},"The document addresses the difficulty of early glioma diagnosis because ctDNA in cerebrospinal fluid is scarce and clears rapidly, causing false negatives and delays in conventional analytical workflows.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the proposed biosensor improve ctDNA detection sensitivity?",{"text":68,"@type":64},"It uses a label-free dual-channel synergistic detection strategy with structural symmetry breaking and momentum condition regulation, integrated with a DNA tetrahedron-hybridization chain reaction-gold nanoparticle cascade amplification system.",{"name":70,"@type":61,"acceptedAnswer":71},"What sensitivity and sample requirements are reported for clinical identification?",{"text":72,"@type":64},"The biosensor achieves an ultra-low detection limit of 74 zM and, in clinical validation, identifies the IDH1.R132H mutation using as little as 1 µL of sample.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354429,1790166904,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061",8,"Advanced Science    \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nA Dual-Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy  \nYu Sun1, 4 Shirui Xu4  \nJing Zhang2, 6 Jingyu Feng1, 5  \nChenqing Liu3 Bin Liu1, 5   \n Jing Lou2 Chao Chang2, 7  \nSihui Wang1, 5  Qinggang Ge4  \nXiangtian Ji1, 5   Jun Yang1, 5   \nXiaofang Zhao1, 5  \n1 Department of Neurosurgery, Peking University Third Hospital, Beijing, P. R. China  2Innovation Laboratory of Terahertz Biophysics, National Innovation Institute of Defense Technology, Beijing, P. R. China  3 Department of Otorhinolaryngology, Head and Neck Surgery, The Sixth Medical Center of the Chinese PLA General Hospital, Beijing, P. R. China  4 Department of Intensive Care Unit, Peking University Third Hospital, Beijing, P. R. China  5 Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Beijing, P. R. China  6Air and Missile Defense College, Air Force Engineering University, Xi’an, P. R. China  7 School of Physics, Peking University, Beijing, P. R. China  \nCorrespondence: Jing Lou ([loujing9486@163.com](loujing9486@163.com))  Chao Chang (gwyzlzssb@pku.edu.cn)  Qinggang Ge (qingganggelin@bjmu.edu.cn)  Jun Yang ([yangjbysy@bjmu.edu.cn](yangjbysy@bjmu.edu.cn))  \nReceived: 9 March 2026  Revised: 9 March 2026  Accepted: 26 March 2026  \nKeywords: Glioma | IDH1 | Liquid Biopsy | Metasurface | QBIC  \nABSTRACT  \nLiquid biopsy technology, which detects circulating tumor DNA (ctDNA) in cerebrospinal fluid, plays a crucial role in the early diagnosis and precision treatment of gliomas. However, the intrinsically low abundance and rapid clearance of ctDNA pose substantial challenges for conventional analytical techniques, such as droplet digital PCR and next-generation sequencing. Here, we introduce a label-free dual-channel synergistic detection strategy that enables quantitative analysis of ctDNA at the zeptomolar level. Leveraging a synergistic design that includes structural symmetry breaking and momentum condition regulation, the optical platform overcomes the inherent structural field confinement and enhances the effectiveness of target-contacted sensing. By integrating a DNA tetrahedron-hybridization chain reaction-gold nanoparticle cascade amplification system, the dual-channel synergistic biosensor achieves an ultra-low detection limit of 74 zM while covering a dynamic range spanning 12 orders of magnitude. Clinical validation has confirmed that this dual-channel synergistic detection strategy can accurately identify the IDH1.R132H mutation in glioma patients with as little as 1 µL of sample, and deliver crucial clinical information such as tumor size and staging. This label-free, rapid, cost-effective, and highly sensitive biosensing platform offers a powerful tool for early cancer screening, molecular diagnostics, and longitudinal disease monitoring.  \n1  Introduction  \nGlioma, one of the most common primary tumors of the central nervous system, accounts for approximately 80% of primary malignant brain tumors [1, 2] . Molecular diagnosis serves asa crucial clinical standard for its management [3, 4] . The isocitrate dehydrogenase 1 (IDH1)-mutant glioma represents a  \ndistinct molecular subtype with high clinical relevance, characterized by a more favorable prognosis and prolonged overall survival [5–8] . Unlike peripheral solid tumors, gliomas cannot be repeatedly biopsied with ease for tissue acquisition [9] . Asa noninvasive approach, liquid biopsy holds great potential for early screening, precision therapy, and disease status evaluation in glioma patients [10, 11] . Due to the unique structure of the  \n\n| Yu Sun, Jing Zhang, and Chenqing Liu contributed equally to this work.\u003Cbr>| |\n| --- | --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Aut","cbCaifwVcUXJ149l","https://ap.wps.com/l/cbCaifwVcUXJ149l","pdf",2364923,12,"English","# Introduction\n## Liquid biopsy and ctDNA limitations in glioma\n## Metasurfaces for enhanced biosensing\n## Rationale for dual-channel synergistic detection strategy","[{\"question\":\"What clinical problem does the document address in glioma liquid biopsy?\",\"answer\":\"The document addresses the difficulty of early glioma diagnosis because ctDNA in cerebrospinal fluid is scarce and clears rapidly, causing false negatives and delays in conventional analytical workflows.\"},{\"question\":\"How does the proposed biosensor improve ctDNA detection sensitivity?\",\"answer\":\"It uses a label-free dual-channel synergistic detection strategy with structural symmetry breaking and momentum condition regulation, integrated with a DNA tetrahedron-hybridization chain reaction-gold nanoparticle cascade amplification system.\"},{\"question\":\"What sensitivity and sample requirements are reported for clinical identification?\",\"answer\":\"The biosensor achieves an ultra-low detection limit of 74 zM and, in clinical validation, identifies the IDH1.R132H mutation using as little as 1 µL of sample.\"}]","A Dual-Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy | PDF",1790110603,30,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2892edccc06911031f4cfe227b55aa6a.webp",983,1283,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f04afb4d6feeb6fba7474fb624b64a6.webp",982,1281,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a55da96ee3495f13fd5ddb826e9ee6a.webp",981,1280,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ece6e22809948b1290ca030d9746d92.webp",980,1279,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":98,"slug":146},"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]